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Abstract 
Bacterial adhesion to human epithelia via lectins constitutes a therapeutic opportunity to prevent 
infection. To enable discovery of compounds able to inhibit bacterial lectins, a virtual screening 
protocol has been iteratively developed via 194 retrospective screening protocols against four 
bacterial lectins (BambL, BC2L-A, FimH and LecA) with known ligands. Specific attention was 
given to the rigorous evaluation of retrospective screening, including calculation of analytical 
errors for enrichment metrics. The developed virtual screening workflow was applied to BambL 
from the lung pathogen Burkholderia ambifaria, predicting 15 active compounds from virtual 
libraries of approximately 7 million compounds. Experimental validation using fluorescence 
polarization confirmed the inhibitory activity for two compounds, which were further 
characterized by titration calorimetry and surface plasmon resonance. This report demonstrates the 
utility of virtual screening protocols, integrating ligand-based pharmacophore filtering and 
structure-based constraints, in the search for bacterial lectin inhibitors.  
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Introduction 
Target dependence of docking protocols and scoring functions is a known obstacle to out-of-the-
box application of structure-based virtual screening.1 Carbohydrate-binding proteins present a 
particularly challenging target type as they exhibit a range of unique ligand-binding features, such 
as formation of hydrogen-bonding networks.2 Therefore, appropriate methodologies need to be 
tailored for these targets, which are involved in many disease processes. For example, in epithelial 
infection, adhesion to human tissues is commonly achieved via binding of cell surface 
carbohydrates by bacterial carbohydrate-binding proteins, termed lectins.3-4 Interfering with this 
binding has been pursued as a new mode of antibacterial therapy, mainly due to the slow selective 
pressure exerted by anti-adhesive agents.5-6 
Inhibition of lectin-carbohydrate binding by glyco-derived compounds has met with promising 
clinical success in human urinary7-8 and respiratory9-10 infections, albeit hampered by the weak 
affinity of lectins for carbohydrates (typically in the milli- to micromolar range). Approaches to 
design efficient lectin inhibitors have explored two main directions: presentation of carbohydrate 
epitopes on multivalent scaffolds (glycodendrimers,11 glycopeptides,12-13 glycoclusters,14-15 and 
glycofullerenes16) and design of glycomimetics, compounds combining carbohydrate character 
with functional groups able to form specific binding interactions or provide avenues for further 
optimization.17 Indeed, small glycomimetics with high affinity are more likely to lead to drug 
development, owing to their more favorable pharmacokinetic properties.18 Such high affinity 
glycomimetic inhibitors have been reported for multiple lectins, including FimH,19-20 LecA,21-23 
LecB,24-26 and BambL.27 
 
4 
BambL (the Burkholderia ambifaria lectin) displays affinity for fucosylated human blood group 
determinants.28 B. ambifaria, a bacterial member of the Burkholderia cepacia complex (BCC), 
was identified in clinical isolates from cystic fibrosis patients,29 a disease in which lectin-mediated 
bacterial adhesion to fucosylated lung epithelia is suspected to play an important role.30-31 
Compounds able to inhibit the BambL-saccharide interaction may have therapeutic potential as 
anti-adhesives. The present study applies our structural knowledge of the BambL binding site 
based on the protein’s crystal structure28 and on our previous simulations of the protein interacting 
with fucosylated oligosaccharides.32 In the latter study, we have determined the atomic interactions 
made by fucosylated carbohydrates recognized by BambL. Each monomer of BambL has two 
independent but very similar binding sites that feature a network of hydrogen bonds within the 
fucose-binding pocket, complemented by interactions with solvent-exposed residues outside the 
binding cleft. Hydrogen-bonding interactions formed by the intramonomeric binding site Arg15, 
Glu26, and Trp79 were most significant for carbohydrate recognition, accompanied by 
hydrophobic stacking against Trp74 and hydrogen-bonding to Ala38 (Figure 1). 
 
Figure 1. BambL-fucose crystallographic complex showing binding interactions. A single 
monomer of the protein is shown in white, carbohydrate shown in yellow with coloring by atom 
type. Hydrogen bonds shown as green dashes. Hydrophobic interactions shown as brown dashes. 
Non-polar hydrogen atoms omitted for clarity. 
 
 
5 
One widely used tool for discovery of novel inhibitors is structure-based virtual screening, an in 
silico approach that rapidly assesses the potential for molecules to interact with a specific binding 
site using molecular docking techniques.1, 33-34 However, reports describing screening against 
carbohydrate-binding proteins often apply virtual screening methods as a “black box”, with neither 
investigations of how well the method would be expected to work (efforts termed retrospective 
screening or validation), nor attempts to improve the screening method. As Grant and Woods35 
pointed out, the docking methods used for carbohydrate virtual screening are typically evaluated 
without negative controls, precluding accurate measurement of the method’s ability to discriminate 
between binders and non-binders. 
In the present work, we set out to iteratively develop and validate a workflow for virtual screening 
against bacterial lectins. Several questions were asked to guide the development of the virtual 
screening workflow: to what degree is carbohydrate screening enrichment artificially enhanced by 
poor camouflage (mismatch in molecular properties between actives and decoys)?; can 
combinations of ligand-based and structure-based screening improve enrichment?; and finally, can 
an enriching screening method unearth novel lectin ligand scaffolds in a prospective search? 
Through extensive method development and evaluation, 194 screening protocols combining 
ligand-based and structure-based screening approaches have been tested using a panel of four 
bacterial lectins with multiple known ligands (BambL, BC2L-A, FimH and LecA). We have paid 
specific attention to the validation aspect, using property-matched carbohydrate decoys and 
calculating analytical errors attending enrichment metrics. Experimental validation of the 
screening approach was carried out via a prospective search for novel inhibitors against BambL. 
Confirmatory bioassays using fluorescence polarization-based competitive binding, surface 
 
6 
plasmon resonance (SPR), and isothermal titration calorimetry (ITC) identified two hit compounds 
showing lectin inhibition. 
 
Methods 
Virtual screening method development 
Selection of actives and decoys 
Target bacterial lectins were selected based on the availability of crystallographic structures, 
glycan array data, and known binding activity for greater than 10 actives. Four lectins were chosen: 
BambL,28 BC2L-A from Burkholderia cenocepacia,36-37 FimH from uropathogenic Escherichia 
coli,38 and LecA from Pseudomonas aeruginosa.39-40 Known actives for these lectins were sourced 
from published literature19-20, 22, 27, 41-53 and from glycan array data deposited in the Consortium for 
Functional Glycomics Gateway database,54 from which unique saccharide actives of 
tetrasaccharide size and smaller were selected. 3D structures of actives were manually constructed 
using Maestro.55 Complete sets of actives are shown in Supplementary Table S1. 
Small molecule decoys were selected from the ZINC database56-58 using the Silico toolkit’s 
molecular property-matching module.59 Decoy selection was based on similarity to the actives in 
the following molecular properties: number of heavy atoms, number of hydrogen bond acceptors 
and donors, number of rotatable bonds, and LogD (predicted using QikProp60). A total of 20 decoys 
were selected per active. The resulting 2D structures were elaborated to corresponding 3D 
structures using LigPrep61 without enumeration of protomers, tautomers, or conformers. 
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Carbohydrate decoys were generated separately for each target lectin by combinatorial assembly. 
For each target, component monosaccharides were chosen to avoid known binding epitopes, then 
assembled in a combinatorial fashion to form di-, tri- and tetrasaccharides using Instant JChem 
reactor modules.62 For example, the target lectin LecA displays affinity for D-galactose epitopes; 
therefore, carbohydrate decoys were assembled from L-fucose, D-glucose, D-mannose, D-N-
acetylgalactosamine, and D-N-acetylglucosamine monosaccharides. Assembly involved 
constructing all glycosidic linkages at all positions on all substrate saccharides, forming all 
possible oligosaccharides. The required number of decoys were randomly selected from each size 
category (i.e., di-, tri-, and tetrasaccharide sizes) to match the distribution of glycan actives from 
glycan arrays. A total of 40 decoys per active were chosen. 
Library preparation 
Three different library compositions were constructed: all actives with ZINC-derived decoys, all 
actives with carbohydrate decoys, and carbohydrate actives (i.e., those derived from glycan arrays) 
with carbohydrate decoys. In each case, Phase63 was used to prepare the library. Compound states 
were generated at pH 7.0 ± 2.0 using Epik.64 Stereochemistry was determined from 3D geometry; 
unspecified stereocenters were sampled, retaining four stereoisomers. Rings were sampled with a 
single conformer retained. High-energy states were removed. For each compound, up to 100 
conformers were kept, with a maximum of 10 conformers retained per rotatable bond. 
Receptor structure preparation 
Crystallographic structures used for structure-based screening are shown bolded in Supplementary 
Table S2. Each receptor structure was truncated to a single chain and prepared using the Protein 
Preparation Wizard implemented within Maestro.64 Bond orders and hydrogen atoms were added, 
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metal coordination bonds and disulfide bonds created, and water molecules removed. Resultant 
models were refined by a restrained minimization of hydrogen atoms only. Receptor grids were 
generated by centering the cubic docking box on the crystallographic bound ligand, with a docking 
box side length of 20 Å and a diameter midpoint box side length of 15 Å. 
Binding pocket constraints 
A single constraint was defined in each lectin binding site as a 1 Å radius sphere centered on the 
most deeply buried ligand atom in the crystallographic complex. In all cases, this corresponded to 
a saccharide hydroxyl oxygen atom. Matching features were set to SMARTS patterns for a single 
carbon, nitrogen, oxygen, or sulfur atom.55 
Pharmacophore hypothesis 
A binding pharmacophore was assembled for each lectin by tallying hydrogen bonding and 
hydrophobic interactions occurring in crystallographic structures (Supplementary Table S3). 
Hydrogen bonds were defined using the Baker-Hubbard method implemented in MDTraj.65 
Hydrophobic interactions were defined as pairs of aliphatic carbon atoms within a 5 Å maximum 
distance, where each carbon atom was bonded only to carbon or hydrogen atoms. Frequently-
interacting ligand features were incorporated into the pharmacophore hypothesis using the 
Develop Hypothesis Model tool in Phase.63 The Advanced Pharmacophore Screening tool was 
used to find pharmacophore matches prior to structure-based screening: database keys were used 
for pre-screening, with tolerance of inter-site matching distances set to 2.0 Å. 
Interaction constraints 
Using the interaction tallies from crystallographic structures, the four most frequently hydrogen-
bonding receptor atoms were used as interaction constraints (Supplementary Table S3). In addition, 
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a single hydrophobic interaction constraint was defined as a 1 Å sphere centered on the 
crystallographic ligand atom most involved in hydrophobic interactions. 
Interaction constraints were applied in multiple configurations: first, a hit was required to 
participate in simultaneous hydrogen bonding interaction with all four atoms, satisfying all four 
interaction constraints (FH method); second, replacement of the least dominant hydrogen bonding 
constraint with a hydrophobic constraint (FI method); third, using all hydrogen bonding and 
hydrophobic constraints while varying the number of required constraint matches from one to four 
(FI-1, FI-2, FI-3, and FI-4), such that hits would be accepted if able to simultaneously satisfy the 
required number of constraints. For BC2L-A, no hydrophobic interactions were detected in 
crystallographic complexes. For both BC2L-A and LecA, binding-site calcium ions are known to 
be significant for ligand binding; these were defined as an interaction constraint alongside 
hydrogen bonding interactions. FimH and LecA complexes feature a broad hydrophobic patch at 
the entrance to the mannose-binding/galactose-binding site, respectively; hydrophobic interaction 
constraints capturing these interactions took the form of a 3.6 Å spherical constraint positioned 
between multiple binding site residues (Supplementary Table S3). During screening, hydrophobic 
constraints were specified to require a bonded carbon and hydrogen atom within the constraint 
radius using the SMARTS pattern C[H]. 
Virtual screening 
Docking calculations were conducted via the Virtual Screening Workflow available within 
Maestro.55 Receptor grids were generated within the screening workflow. To investigate the effect 
of different active-decoy set combinations on screening enrichment, three library compositions 
were investigated for each lectin: all actives – ZINC-derived decoys, all actives – carbohydrate 
decoys, and carbohydrate actives – carbohydrate decoys (Figure 2A). Screening was performed on 
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each input library using the HTVS algorithm. Additionally, each screen was also performed using 
the Glide HTVS algorithm followed by a re-screening step using the Glide SP algorithm;66-67 in 
these, the top-ranked 10% of hits were re-docked using SP mode, with enhanced sampling enabled 
and retaining only the highest-scoring state of each compound. The following protocols, 
summarized in Figure 2B, were tested in this investigation. Default: structure-based screening 
conducted using entirely default settings. F: input library filtering using ligand pharmacophore 
matching as described above followed by structure-based screening using default settings. FP: 
input library filtering followed by structure-based screening using a binding pocket constraint. FH: 
input library filtering followed by structure-based screening using four hydrogen bonding and 
metal coordination interaction constraints. FI: input library filtering followed by structure-based 
screening with the least-dominant hydrogen bonding constraint replaced by a hydrophobic 
constraint, maintaining a total of four required constraints. Finally, this screen was repeated with 
all hydrogen bonding and hydrophobic constraints, varying the number of required constraints 
from one to four. In total, 194 screening protocols were tested in an iterative fashion 
(Supplementary Tables S4 and S5). 
 
Figure 2. Schematic depicting (A) composition of active and decoy sets and (B) retrospective 
screening protocols evaluated. 
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Enrichment metrics were calculated using the Silico toolkit.59 For both ROC AUC and ROC-based 
Enrichment Factor, analytical errors were calculated according to the method communicated by 
McGann et al.68 
Prospective virtual screening library preparation 
Two large molecular databases were screened prospectively: the eMolecules Screening Library 
(approximately 7 million compounds) and the Otava Ltd. Catalogue and Glycomimetic Collection 
(containing 246 compounds). Web-based substructure search tools were used to extract 
compounds containing a SMILES string CXC(C)C(O)CX, where X = O for the eMolecules 
Screening Library and O/N for the Otava Ltd. catalogue. The total number of input compounds 
collected from eMolecules and Otava databases was 11,705. The Generate Phase Database module 
of Phase63 was used to prepare the virtual library compounds by adding hydrogens and generating 
conformers (up to a maximum of 100 conformers per compound). Tautomers were enumerated at 
pH 7.0 using Epik.64 Stereochemistry was determined from 2D parities where present; where 
absent, a maximum of four stereoisomers were retained per compound. Rings of five and six 
members were sampled, retaining one ring conformation per compound. Virtual screening was 
performed using the FI method as described above: after applying the ligand-based pharmacophore 
filter, resulting matches were screened using the HTVS algorithm. The top-ranked 10% of hits 
were then re-screened using the SP algorithm with enhanced sampling enabled, retaining only the 
highest-scoring state of each compound. Finally, the top 10% of hits were manually inspected, 
removing undesirable compounds (simple monosaccharides, compounds of molecular weight 
higher than 600 g/mol, compounds containing free thiols, and commercially unavailable 
compounds). 
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Isothermal titration calorimetry 
Recombinant BambL was produced and purified as previously described by Audfray et al.28 The 
protein was dissolved in buffer (20 mM Tris/HCl pH 7.5, NaCl 100 mM with CaCl2 100 µM). The 
protein concentration was checked by measuring A280 using a theoretical molar extinction 
coefficient of 40,450 M-1 cm-1. Isothermal titration calorimetry (ITC) was performed with an 
ITC200 microcalorimeter (MicroCal, Inc). The BambL solution (50 µM) was placed in the 200 
µL sample cell at 25 °C. Ligands were dissolved in the same buffer to a concentration of 1 mM, 
and loaded in the injection syringe. Titration was performed using 20 injections of 1 µL volume 
of ligand solution, which were spaced at 120 second intervals and injected for a duration of 2 
seconds each. Where binding isotherms were observed, data were fitted with MicroCal Origin 7 
software, according to standard procedures, using a 1:1 binding site model. Fitted data yielded the 
stoichiometry (n), the association constant (Ka) and the enthalpy of binding (ΔH). Other 
thermodynamic parameters (i.e. changes in free energy ΔG, and entropy ΔS) were calculated from 
the equation ΔG = ΔH – TΔS = RTlnKa in which T is the absolute temperature and R = 8.314 J 
mol-1 K-1. Three independent titrations were performed for each ligand tested. 
Surface plasmon resonance 
Surface plasmon resonance (SPR) experiments were performed on a Biacore X100 instrument (GE 
Healthcare) at 25°C in HBS (10 mM Hepes/NaOH, pH 7.4, 150 mM NaCl, 0.05% Tween 20 and 
3 mM EDTA) at a flow rate of 30 μL min-1. Streptavidin (100 μg mL-1) was immobilized on a 
research grade CM5 dextran chip using amine coupling (3029.6 resonance units of streptavidin 
were fixed in channel 1, 2939.5 resonance units in channel 2). Biotin capture was then conducted 
to affix biotinylated polyacrylamide (PAA) probes (Lectinity, 200 μg mL-1) bearing galactose or 
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fucose to channels 1 (PAA-galactose, 375 resonance units) and 2 (solution containing 90% PAA-
galactose and 10% PAA-fucose, total of 447.5 resonance units). Inhibition experiments were 
performed with the fucosylated channel 2, and plots represent the subtracted data (channel 2 – 
channel 1). Inhibition studies consisted of the injection (association 180 s, dissociation 180 s) of 
incubated (>30 min at room temperature) mixtures of BambL (0.8 µM) and various concentrations 
of inhibitor (2-fold cascade dilutions from 200 to 0.2 µM). For each inhibition assay, BambL was 
injected to observe the full adhesion of the lectin onto the sugar-coated surface (0% inhibition). 
The chip was regenerated by injection of 1 M fucose in running buffer for 80 s. Binding was 
measured as resonance units over time after blank subtraction, and data were then evaluated by 
using the Biacore X100 evaluation software, version 2.0. For IC50 evaluation, the response was 
taken as the amount of lectin bound to the sugar-coated surface at equilibrium in the presence of a 
defined concentration of inhibitor. Inhibition curves were obtained by plotting the percentage of 
inhibition against the inhibitor concentration. 
Competitive binding using fluorescence polarization 
Assays were conducted as previously established for LecB25, 69 and other bacterial lectins.41, 70-71 
A 60 μL solution containing lectin (225 nM for LecB, 150 nM for BambL) and reporter ligand 
FITC-fucoside25 (1.5 nm for LecB, 75 nM for BambL) in TBS buffer was added to 30 µL serial 
dilutions of testing compounds in TBS (in duplicates for LecB, single serial dilution for BambL) 
in black 96-well Costar plates (Fisher Scientific, France, cat. no.: 06-443-2). Concentration ranges 
were selected for each compound to cover the range over which inhibitory activity was visible. 
For LecB, α-methyl fucoside, α-methyl mannoside and L-Fucα1-6[D-GlcNAcβ1-4]D-GlcNAcβ1-
OMe were prepared in 5-fold dilutions from 33.3 mM to 400 nM, and 2-deoxy-2-fluoro-L-fucose 
was prepared using 2-fold dilutions from 25 mM to 0.195 mM. For BambL, concentration ranges 
 
14 
were selected for each compound using 5-fold dilutions for: α-methyl fucoside (3.33 mM to 213 
nM), L-Fucα1-6[D-GlcNAcβ1-4]D-GlcNAcβ1-OMe (3.33 mM to 42.6 nM), and 2-deoxy-2-fluoro-
L-fucose (16.6 mM to 213 nM). After addition of the reagents, the plates were sealed with film and 
shaken for 4 hours in darkness at room temperature. Fluorescence polarization was measured on a 
BMG LABTECH CLARIOstar multi-mode microplate reader (BMG LABTECH GmbH) with 
excitation filters at 482-16 nm and emission filters at 530-40 nm. The data were analyzed with 
Graphpad Prism 6 and fitted according to the four-parameter variable slope model. 
 
Results 
Virtual screening optimization for bacterial lectins 
Selection of target lectins, actives, and decoys 
The BambL, BC2L-A, FimH, and LecA lectins were chosen for virtual screening optimization. 
For each lectin, decoy compounds were selected from the ZINC database to approximate the 
molecular properties of known actives as described in the Methods. The molecular properties of 
ZINC decoys proved a poor match for the molecular properties of active compounds (shown for 
BambL in Table 1, for all four lectins in Supplementary Figure S1). A second set of decoy 
compounds was therefore assembled, which exhibited closer property-matching, except for the 
number of rotatable bonds. Both decoy sets were used for retrospective screening to compare the 
effect of decoy property-matching on retrospective enrichment. 
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Table 1. Average molecular properties for BambL actives and decoys. 
Compound set 
Heavy 
atom 
count LogD 
Rotatable 
bonds 
H-bond 
acceptor 
H-bond 
donor 
Actives 31.7 -4.2 5.8 12.8 8.3
Actives (Carbohydrate only) 32.5 -4.6 6.1 13.4 8.8
ZINC 25.8 -1.2 5.6 6.9 3.8
Carbohydrate decoys 37.6 -6.2 8.2 16.0 11.0
Virtual screening method development 
The docking software Glide predicts ligand placements within protein binding sites. When docking 
calculations are performed in a high-throughput manner, Glide may be used to predict binding 
activity for large collections of molecules. Glide has demonstrated appreciable docking accuracy 
for carbohydrate-binding proteins in general2, 72-73 and for bacterial lectins specifically.74-75 
A virtual screening workflow was developed using Glide66-67 over a total of 194 retrospective 
virtual screens spanning all target and active/decoy sets. The multiple methods explored during 
the iterative workflow development are summarized in Figure 2. The left panel (Figure 2A) 
indicates the three compositions of active and decoy sets trialled for each lectin (note that 
carbohydrate actives were not combined with ZINC decoys). The various screening protocols 
performed are summarized in the right panel (Figure 2B). 
Iterative development of the virtual screening method explored combinations of pharmacophore 
filters, binding site constraints and protein-ligand interaction constraints over a total of 194 
screening experiments. Filters were applied in a ligand-based manner prior to structure-based 
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screening, while constraints were applied during structure-based screening to enforce the 
placement of ligand atoms either within the general binding site, or in positions able to form 
selected interactions with the lectin. Development of a screening method began with an entirely 
‘default’ approach, to which pharmacophore filters were subsequently added (‘F’). Binding pocket 
constraints were applied (‘FP’), and then exchanged for hydrogen-bonding interaction constraints 
(‘FH’) and for general protein-ligand interaction constraints (‘FI’). The above screening methods 
were each conducted using two scoring protocols implemented within Glide: High-Throughput 
Virtual Screening (HTVS) alone, and in conjunction with Standard Precision scoring (HTVS-SP). 
Overall enrichment was measured using linear ROC AUC (Supplementary Table S4), which 
expresses the probability that an active compound will be ranked higher than a decoy (henceforth 
referred to as “AUC”). An AUC of 0.5 represents essentially random ranking of actives, while an 
AUC of 1.0 corresponds to perfect ranking of all actives above all decoys. AUC accords the same 
weight to rankings of actives throughout the hitlist, making the metric equally sensitive to actives 
present at the start and end of the hitlist. Since the early portion of the hitlist is of greater interest 
for prospective virtual screening, a metric more sensitive to early predictive ability was also 
employed. Specifically, to measure early enrichment, the ROC-based enrichment factor EF 
(Supplementary Table S5) was used, which describes the fraction of actives found once a fixed, 
chosen fraction of inactives have been found (here, set to 10%). By selecting inactive fractions in 
the early regions of the ROC curve, a method’s ability to rank actives above decoys in the early 
portions of the hitlist can be measured. Both scoring protocols HTVS and HTVS-SP achieved very 
similar enrichments in most experiments (Supplementary Tables S4 and S5). Below quoted results 
were determined using the HTVS-SP protocol. Analytical errors were calculated for both AUC 
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and EF, and were taken into account in the comparisons between screening protocols. Where 
necessary, error values are quoted. 
BambL 
When property-matched ZINC-derived decoys were spiked with all actives (Figure 3, green), 
structure-based screening with default parameters achieved high overall enrichment (AUC: 0.83; 
Figure 3A). Addition of a ligand pharmacophore filter (F) and a binding pocket constraint (FP) 
enhanced early enrichment (EF: 5.33 → 8.67 [F], 8.00 [FP]; Figure 3B), but not overall enrichment 
(AUC: 0.86 [F], 0.80 [FP]). Enrichment was decreased by the use of four hydrogen-bonding (FH) 
and interaction (FI) constraints, both early (EF: 6.67 [FH, FI]; Figure 3B) and overall (AUC: 0.67 
[FH, FI]; Figure 3A). Inspection of the ROC profiles for these experiments (data not shown) 
revealed truncated curves, indicating that interaction constraints were overly restrictive. Methods 
relaxing the number of required interaction constraints were therefore evaluated (FI-1, FI-2, FI-3, 
FI-4). By reducing the number of required constraint matches from the initial four to one or two, 
overall enrichment was substantially improved (AUC: 0.93 [FI-1], 0.92 [FI-2]; Figure 3C). 
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Figure 3. Overall and early enrichment represented by ROC curve metrics for BambL HTVS-SP 
screening. (A) Overall enrichment for default, F, FP, FH, and FI protocols. (B) Early enrichment 
for default, F, FP, FH, and FI protocols. (C) Overall enrichment for FI-1, FI-2, FI-3, and FI-4 
protocols. (D) Early enrichment for FI-1, FI-2, FI-3, and FI-4 protocols. Green: ZINC-derived 
decoys with all actives; yellow: carbohydrate decoys with all actives; blue: carbohydrate decoys 
with carbohydrate actives only. Error bars show the analytically calculated standard deviation. 
 
Early enrichment was also significantly higher when using fewer required constraint matches (EF: 
9.33 [FI-1, FI-2]; Figure 3D). Carbohydrate decoys, with either all or carbohydrate actives (yellow 
and blue bars in Figure 3, respectively) yielded similar enrichment results for most protocols. 
However, when using the optimal protocols FI-1 or FI-2, the early enrichment was lower with 
carbohydrate decoys, compared to ZINC-derived ones (Figure 3D). This finding demonstrated a 
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more discriminating character of carbohydrate decoys, which would result in a more robust method 
validation via retrospective screening. 
BC2L-A 
Overall enrichment for BC2L-A was not significantly altered by the use of a pharmacophore filter 
(F) or binding pocket constraints (FP) (Supplementary Table S4). Early enrichment measures 
likewise remained within range of analytical error between experiments (Supplementary Table S5). 
In screening of all actives against ZINC decoys, the introduction of four simultanously applied 
hydrogen-bonding constraints drastically reduced enrichment (AUC: 0.58 ± 0.07 [default] → 0.12 
[FH]). Relaxing the number of required constraints to one was able to restore the overall 
enrichment (AUC: 0.65 ± 0.07 [FI-1]). Screening all actives against carbohydrate decoys 
performed similarly to screening against ZINC decoys. However, screening using only 
carbohydrate actives, with any number of interaction constraints (FI-1, FI-2, FI-3, and FI-4), 
returned no active compounds (Supplementary Tables S4 and S5). For this target lectin, 
enrichment relied strongly on the presence and ranking of non-carbohydrate actives. 
FimH 
Both overall and early enrichment against ZINC decoys was significantly improved by the use of 
a pharmacophore filter (AUC: 0.72 [default] → 0.82 [F], EF: 4.41 [default] → 7.94 [F]; 
Supplementary Tables S4 and S5). Use of a binding pocket constraint (FP) and hydrogen-bonding 
constraints (FH) maintained the boost to early enrichment while decreasing overall enrichment. 
Introduction of a hydrophobic constraint severely reduced both overall and early enrichment (AUC: 
0.18 [FI]; EF: 1.76 [FI]). Relaxing the number of required constraint matches rescued the 
enrichment. Specifically, a single required constraint matched the highest overall and early 
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enrichment to within the analytical error (AUC: 0.81 [FI-1]; EF: 7.65 [FI-1]). Carbohydrate decoys 
reduced overall enrichment using this protocol, more so for input containing only carbohydrate 
actives (AUC: 0.67). Early enrichment dropped from 7.65 to 5.00 and 2.22, for all and 
carbohydrate actives, respectively (Supplementary Table S5). Again, similar to BambL, these 
decreases demonstrated the greater discriminating power of carbohydrate decoys, compared to 
non-carbohydrate ones. 
LecA 
In general, screening performance for LecA was poorer than for other target lectins 
(Supplementary Tables S4 and S5). Using ZINC decoys, default screening settings discriminated 
against actives, performing worse than random selection (AUC: 0.49 [default]). Use of a 
pharmacophore filter improved overall enrichment slightly (AUC: 0.67 [F]), while the addition of 
any style of constraints returned both overall and early enrichment to random (AUC: 0.49 [FP]) or 
null (FH, FI) values. In particular, using any number of interaction constraints returned no active 
compounds. Screening using carbohydrate decoys performed similarly to ZINC decoys in all 
respects, yielding at best only random selection of actives. 
In summary, retrospective screening enrichment at three out of four bacterial lectins benefited from 
the use of pharmacophore filters and application of only one or two interaction constraints, with 
greater numbers of constraints proving detrimental to enrichment. Significantly, the use of 
carbohydrate decoys was demonstrated to be most appropriate in order to evaluate a virtual 
screening methodology for application to carbohydrate-binding targets. 
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Prospective screening against BambL 
After the developed virtual screening method demonstrated consistent enrichment at BambL, a 
prospective screen using the same method was conducted in search of novel inhibitory chemistry. 
The workflow shown in Figure 4 was used to select compounds, from the eMolecules Screening 
Compounds library and OTAVA Ltd. catalogue, with potential to inhibit the BambL protein. The 
workflow corresponds to the FI-2 screening method developed above, featuring a ligand-based 
pharmacophore filter to rapidly remove compounds lacking the atomic features required for 
binding, followed by a structure-based docking screen with binding interaction constraints to 
remove compounds unable to complement the BambL binding site architecture (see 
Supplementary Table S3 for constraint details). Manual selection according to the criteria outlined 
above identified 15 candidate compounds for experimental evaluation against BambL 
(Supplementary Figure S2). 
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Figure 4. Workflow of the virtual screening protocol used for prospective screening at BambL. 
 
Experimental validation of predicted compounds against BambL 
Experimental activity of the 15 selected compounds towards BambL was first evaluated using 
fluorescence polarization assays developed for this purpose. The fluorescence polarization assay 
method, originally developed by Hauck et al.25 for studying binding to LecB (another fucose-
binding bacterial lectin) and other lectins,41, 70-71 has been applied to BambL. The assay measures 
displacement of a fluorescein-labeled reporter ligand FITC-fucose (N-(fluorescein-5-yl)-N’-(α-L-
fucopyranosyl ethylen)-thiocarbamide) from the lectin binding site by the inhibitor under 
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consideration. Here, this assay was used to evaluate the manually-selected virtual screening hits 
for inhibition of BambL and LecB. 
Fucα1-OMe and Manα1-OMe (Figure 5) were also evaluated by fluorescence polarization, for 
comparison. Two screening hits showed ability to bind to BambL (Figure 5). Compounds 1 and 2 
are entirely composed of carbohydrate rings, and both contain a fucose saccharide. Compound 1 
showed lower inhibition of BambL-probe binding (Figure 6; IC50 19.9 μM), compared to Fucα1-
OMe (IC50 2.4 μM). Inhibition by compound 2 was similar (Figure 6; IC50 1.4 μM) to Fucα1-OMe. 
Since compound 2 contains an unmodified fucose saccharide, similar inhibitory activity was 
expected. Inhibition of LecB-FITC-fucose binding by compound 2 was intermediate between 
Fucα1-OMe and Manα1-OMe, while compound 1 was less active than either control saccharide 
(IC50 >> 1 mM). 
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Figure 5. Fucose monosaccharide, mannose monosaccharide, and virtual screening hit compounds 
showing inhibitory activity towards BambL.  
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Figure 6. Fluorescence polarization evaluation of competitive inhibition of BambL and LecB by 
virtual screening hit compounds. All replicate measurement values are shown (single measurement 
for BambL, duplicate measurement for LecB). (A) Titration of FITC-fucose with BambL reveals 
specific binding at probe compound concentrations of 10 nM (triangles, EC50 120 μM), 50 nM 
(squares, EC50 195 μM), and 90 nM (circles, EC50 193 μM). (B) Compared to Fucα1-OMe (squares, 
IC50 2.4 μM), hit compounds inhibit the BambL-probe association with similar affinity (2, circles, 
IC50 1.4 μM) or poorer affinity (1, triangles, IC50 19.9 μM). (C) Inhibition of the LecB-probe 
association by 2 (squares, IC50 5.5 μM) is intermediate in affinity between Fucα1-OMe (circles, 
IC50 1.1 μM) and Manα1-OMe (triangles, IC50 230 μM). 1 displays poorer affinity for LecB, with 
IC50 values greater than 1 mM (data not shown).  
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Isothermal titration calorimetry confirmed direct binding of both compounds to BambL in a one-
site fitting model (Table 2, Figure 7), revealing essentially identical interactions with both the 
intra- and inter-monomeric binding sites. Both compounds exhibited dissociation constants in the 
micromolar range (1: KD of 18.8 ± 2.3 μM; 2: KD of 1.0 ± 0.1 μM), with lectin binding characterized 
by a greater enthalpic, rather than entropic component of binding. Despite the large difference in 
molecular size, the magnitude of the entropic component of binding is similar between 1 and 2. 
BambL inhibition data from these two solution-based assay methods (fluorescence polarization 
and ITC) display excellent agreement. 
 
Table 2. Titration microcalorimetry data for binding to BambL. Experiments were performed in 
triplicate; values shown are mean ± SD. 
Ligand n KD (μM) ΔG (kJ∙mol-1) ΔH (kJ∙mol-1) TΔS (kJ∙mol-1) 
Fucα1-OMe 1.90 ± 0.01 1.5 ± 0.2 –33.2 ± 0.3 –41.9 ± 0.5 –8.7 ± 0.7
1 1.92 ± 0.09 18.8 ± 2.3 –27.0 ± 0.3 –31.3 ± 1.6 –4.2 ± 1.9
2 1.81 ± 0.12 1.0 ± 0.1 –34.2 ± 0.3 –38.2 ± 0.4 –4.0 ± 0.8
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Figure 7. Thermograms in the upper panels were obtained by titration of BambL (50 µM) with 
virtual screening hit compounds (1, left; 2, right) at 1 mM. Binding isotherms in the middle panels 
show the heat released as a function of total ligand concentration (shown as a molar ratio to the 
protein concentration). The solid lines indicate the best least-squares regression fit line to the 
experimental data, using a one-site binding model. Each titration was conducted in triplicate, with 
each replicate fitted individually (shown as black triangles, blue squares, and grey circles). Error 
bars show the variation in integrated heat peak area encountered during peak-shape analysis. 
Residuals in the bottom panels indicate the quality of the regression fit for the correspondingly-
coloured replicate. 
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In surface plasmon resonance assays (Figure 8), BambL inhibition by virtual screening hits was 
less detectable (1: IC50 of 166 μM; 2: IC50 of 10.7 mM). The inhibition efficiency (IC50) of these 
hit compounds was lower than apparent affinity in solution assays. This could be explained by the 
strong avidity of BambL for multivalent surfaces, which is difficult to compete with when using 
monovalent ligands. 
 
Figure 8. Normalized inhibition by virtual screening hit compounds of BambL-fucosylated 
polyacrylamide association measured by SPR. Fucα1-OMe showed the greatest inhibitory ability 
(circles, IC50 24.1 μM), followed by 1 (squares, IC50 166 μM) and 2 (triangles, IC50 10.7 mM). 
 
Discussion 
767778The majority of virtual screening studies against carbohydrate-binding proteins do not 
evaluate the applied method nor use negative controls/decoys to establish retrospective 
enrichment.79-84 Validation is critical for the improvement of screening methods against these 
targets, and allows users to judge the transferability of reported successes. Where retrospective 
screening has been performed, enrichment indicators used include the raw number of hits 
returned,85 the ratio of retrieved actives to total actives,86-87 and the widely-used 1% Enrichment 
Factor88 and ROC AUC.8987-8889[EY1] 
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In this work, a virtual screening protocol for bacterial lectins was iteratively developed and 
evaluated using the ROC Enrichment Factor and ROC AUC metrics, with calculation of standard 
errors. The influence of decoy types on retrospective virtual screening enrichment was also 
examined. The virtual screening workflow was applied prospectively to BambL for identification 
of novel inhibitors; two of the identified hits consistently showed lectin inhibition in biophysical 
assays. 
Decoy selection in this study was guided by two related considerations: avoiding known epitopes 
in decoys while matching decoys to actives in physical property space. Specifically, carbohydrate 
decoys were built from monosaccharides, excluding those with known specificity for a given lectin, 
as shown by experimental glycan array data. In that sense, these decoys are confirmed non-binders. 
Non-carbohydrate decoys were drawn from ZINC, and are assumed to be non-binders based on 
the absence of carbohydrate epitopes in their structures. This type of assumption is a known caveat 
in virtual screening studies.90 With respect to the second consideration, many have noted that 
retrospective screening enrichement depends on the resemblance between actives and decoys.91-92 
Our results are consistent with this observation, showing that enrichment in retrospective screens 
against bacterial lectins was influenced by the nature of the decoy compounds. Enrichment 
obtained using all actives may be artificially inflated by poor physical property-matching (either 
between ZINC-derived decoys and carbohydrate actives, or between carbohydrate decoys and non-
carbohydrate actives). In contrast, the poorer enrichment obtained using carbohydrate decoys with 
carbohydrate actives in these screens provides a more genuine measure of the expected enrichment 
in a prospective virtual screening against carbohydrate-binding proteins. 
Iterative development of a virtual screening workflow explored combinations of ligand-based and 
structure-based screening techniques. As noted above, the use of binding pocket constraints and 
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interaction-based constraints have not been previously applied to carbohydrate-binding proteins. 
In general, pharmacophore-based filtering improved enrichment compared to the entirely default 
screening setup. Subsequent addition of a binding pocket constraint also provided a small increase 
to enrichment. Interaction-derived constraints were initially applied in full force (i.e., requiring 
simultaneous formation of four binding interactions), causing a decrease in both early and overall 
enrichments. However, once the number of simultaneously-required constraints was reduced, 
enrichment measures increased again, affording the greatest enrichment for BambL and FimH. 
These retrospective screening experiments demonstrate that a combination of ligand-based and 
structure-based techniques enhance enrichment against against carbohydrate-binding proteins. 
In our previous efforts,32 we have determined the atomic interactions made by fucosylated 
carbohydrates recognized by BambL. BambL-carbohydrate binding involved a network of 
hydrogen bonds within the fucose-binding pocket as well as interactions with satellite solvent-
exposed residues outside of the binding cleft. The interacting residues identified in our earlier work 
were now used to define interaction constraints for prospective virtual screening. For BambL, the 
two-match interaction constraint screening method (FI-2) was genuinely able to prioritize binders 
over non-binders. Application of the FI-2 screening workflow to BambL identified 15 compounds 
with predicted binding affinity for BambL. Lectin inhibition was confirmed for two of these using 
fluorescence polarization, SPR, and ITC assays. 
Compound 2 is a component of naturally occurring N-glycans such as Nod factors (signalling 
molecules produced by symbiotic bacteria at legume roots).93 N-glycans carrying the fucosylated 
chitobiose epitope, present in compound 2, display binding affinity toward BambL in glycan array 
data from the Consortium for Functional Glycomics. In solution-based assays (fluorescence 
polarization and ITC), compound 1 (2-deoxy-2-fluoro-L-fucose) displays excellent affinity for 
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BambL in the same range as natural fucose. Substitution of carbohydrate hydroxyl groups by 
fluorine has been demonstrated in some cases to enhance affinity for protein receptors (e.g., 
Toxoplasma gondii TgMIC1,94 Mycobacterium tuberculosis UDB-galactopyranose95). Since 
fluorine substitution can give rise to lectin specificity, we tested the binding of compound 1 to a 
second fucose-binding bacterial lectin, LecB from P. aeruginosa. 
The fucomimetic compound 1 displayed a difference in inhibitory activity between lectins BambL 
and LecB. In fluorescence polarization assays (Figure 6), compound 1 inhibited BambL-probe 
binding with an IC50 of 19.9 μM, while barely inhibiting LecB-probe binding (IC50 >> 1 mM), an 
observation that confirms previous experiments with related 1,2-dideoxy-2-fluoro-L-fucose and 
LecB.41 A structural rationale for this observation can be suggested. In the LecB-fucose 
complex,96-98 the fucose 2-position hydroxyl oxygen directly coordinates one of the two binding 
site calcium ions and forms a hydrogen bond to Asp99. Thus, the substitution of hydroxyl by 
fluorine is not favorable for binding. The BambL-fucose complex features a hydrogen bond 
donated by the backbone amide nitrogen of Asp38 to the fucose 2-position hydroxyl.28 Therefore, 
in this case, fluorine can act as a weak hydrogen bond acceptor, making the substitution more 
acceptable. Compound 1 is therefore an excellent hit compound for the development of a specific 
inhibitor for BambL and related lectins. 
 
Conclusion 
Through iterative development and retrospective evaluation, a virtual screening workflow for 
bacterial lectins was developed. For two target systems, BambL and FimH, molecular properties 
of decoy compounds were found to exert influence upon retrospective enrichment. This finding 
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showed that enrichment in virtual screening against carbohydrate-binding proteins could be 
artificially enhanced by poor decoy camouflage. In addition, the presence of non-carbohydrate 
actives was also conducive to over-estimated enrichment. Combined ligand-based and structure-
based screening techniques were demonstrated to improve retrospective enrichment via the use of 
interaction-based constraints. For BambL, enforcing two interaction constraint matches provided 
the greatest overall enrichment in retrospective screening. A prospective virtual screen for 
compounds able to bind to BambL yielded two inhibitory molecules. Compound 1 (2-deoxy-2-
fluoro-L-fucose) displayed slightly reduced affinity for BambL compared to L-fucose, but multiple 
orders-of-magnitude reduction in affinity for LecB. The fucose 2-position is therefore suggested 
as an opportunity for designing selectivity for BambL in preference to other fucose-binding lectins. 
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